Comparative Pharmacology
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus NYSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus NYSTATIN.
HEAD & SHOULDERS CONDITIONER vs NYSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable; this is a cosmetic conditioner. No pharmacological mechanism.
Nystatin binds to sterols in the fungal cell membrane, primarily ergosterol, altering membrane permeability and causing leakage of intracellular components, leading to fungal cell death.
Not applicable. Head & Shoulders Conditioner is a cosmetic product for external use on hair and scalp; no systemic dosing.
Oral: 500,000 to 1,000,000 units (5-10 mL suspension) swish and swallow 3-4 times daily; Vaginal: 1 vaginal tablet (100,000 units) once or twice daily; Topical: Apply cream/ointment 2-3 times daily; duration depends on indication.
None Documented
None Documented
Not applicable for systemic elimination; local retention on hair/scalp lasts until next wash (typically 24-48 hours).
Clinical Note
moderateNystatin + Tranilast
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast."
Clinical Note
moderateNystatin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tolfenamic acid."
Clinical Note
moderateNystatin + Nimesulide
"The risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide."
Clinical Note
moderateNystatin + Risedronic acid
Due to minimal systemic absorption, a terminal elimination half-life is not clinically relevant. In vitro plasma degradation half-life is approximately 1.5 hours, but this is not applicable in vivo.
Renal (urine): <1% unchanged; biliary/fecal: <1% as parent compound; majority remains on hair/scalp and is removed via washing and shedding. Systemic absorption negligible.
Nystatin is not absorbed from the gastrointestinal tract after oral administration; virtually 100% of the ingested dose is excreted unchanged in the feces. After topical application, systemic absorption is negligible; any absorbed drug is excreted via bile and feces (<1% renal).
Category C
Category A/B
Antifungal/Antidandruff
Antifungal
"The risk or severity of adverse effects can be increased when Nystatin is combined with Risedronic acid."